Revance Therapeutics, Inc.

RVNC Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Insiders
Institutions
Government

Chart provided by TradingView

Income
Balance Sheet
Cash Flow
RVNC Income Statement
RVNC Balance Sheet
RVNC Cash Flow
Congress Trading

Recent trades of RVNC by members of U.S. Congress

Politician Type Traded
Thomas R. Carper Senate / D Purchase $1,001 - $15,000 Oct. 04, 2023
RVNC Stock Insider Trading Activity
Name
Type
Shares
Price
Shares Held
Date
Reported
RVNC Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
RVNC Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported
Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by RVNC's directors and management

Corporate Lobbying

Government lobbying spending instances

  • $20,000 Jul 19, 2024 Issue: Health Issues
  • $20,000 Apr 17, 2024 Issue: Health Issues
  • $20,000 Oct 20, 2023 Issue: Health Issues
  • $20,000 Jul 20, 2023 Issue: Health Issues
  • $20,000 Apr 17, 2023 Issue: Health Issues
  • $20,000 Jan 18, 2023 Issue: Health Issues
  • $20,000 Oct 20, 2022 Issue: Health Issues
  • $20,000 Jul 20, 2022 Issue: Health Issues
  • $20,000 Apr 20, 2022 Issue: Health Issues
  • $20,000 Jan 18, 2022 Issue: Health Issues
  • $20,000 Oct 23, 2021 Issue: Health Issues
  • $20,000 Jul 22, 2021 Issue: Health Issues
  • $20,000 Apr 21, 2021 Issue: Health Issues
  • $10,000 Jan 20, 2012 Issue: Pharmacy
  • $10,000 Jan 12, 2012 Issue: Government Issues
  • $10,000 Jan 12, 2012 Issue: Government Issues
  • $10,000 Oct 17, 2011 Issue: Pharmacy
  • $10,000 Jul 14, 2011 Issue: Pharmacy
Corporate Lobbying

Estimated quarterly lobbying spending

U.S. Patents

New patents grants

  • Patent Title: Albumin-free botulinum toxin formulations Feb. 27, 2024
  • Patent Title: Topical ocular preparation of botulinum toxin for use in ocular surface disease Nov. 01, 2022
  • Patent Title: Injectable botulinum toxin formulations Oct. 18, 2022
  • Patent Title: Methods and systems for purifying non-complexed Oct. 11, 2022
  • Patent Title: Albumin-free botulinum toxin formulations Jun. 07, 2022
  • Patent Title: Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds Dec. 08, 2020
  • Patent Title: Compositions and methods for topical application and transdermal delivery of botulinum toxins Aug. 18, 2020
  • Patent Title: Botulinum toxin and the treatment of primary disorders of mood and affect Oct. 15, 2019
  • Patent Title: Compositions and methods for safe treatment of rhinitis Feb. 12, 2019
  • Patent Title: Compositions and methods for topical diagnostic and therapeutic transport Jan. 08, 2019
  • Patent Title: Albumin-free botulinum toxin formulations Oct. 30, 2018
  • Patent Title: Methods for treating pain by topical application and transdermal delivery of botulinum toxin Sep. 25, 2018
  • Patent Title: Injectable botulinum toxin formulations May. 01, 2018
  • Patent Title: Extended length botulinum toxin formulation for human or mammalian use Apr. 24, 2018
  • Patent Title: Topical ocular preparation of botulinum toxin for use in ocular surface disease Feb. 27, 2018
  • Patent Title: Methods and systems for purifying non-complexed botulinum neurotoxin Oct. 18, 2016
  • Patent Title: Albumin-free botulinum toxin formulations May. 17, 2016
  • Patent Title: Compositions and methods for topical application and transdermal delivery of botulinum toxins Apr. 19, 2016
  • Patent Title: Compositions and methods for topical application and transdermal delivery of botulinum toxins Dec. 15, 2015
  • Patent Title: Compositions and methods for topical application and transdermal delivery of botulinum toxins Nov. 10, 2015
  • Patent Title: Compositions and methods for topical diagnostic and therapeutic transport Mar. 10, 2015
  • Patent Title: Multi-component biological transport systems Feb. 24, 2015
  • Patent Title: Arginine heteromers for topical administration Aug. 26, 2014
  • Patent Title: Arginine heteromers for topical administration Jan. 14, 2014
  • Patent Title: Antimicrobial peptide, compositions, and methods of use Jan. 07, 2014
  • Patent Title: Compositions and methods for treating acne Nov. 12, 2013
  • Patent Title: Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins Oct. 29, 2013
  • Patent Title: Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins Aug. 27, 2013
  • Patent Title: Compositions and methods for topical application and transdermal delivery of botulinum toxins Mar. 26, 2013
  • Patent Title: Compositions and methods for topical application and transdermal delivery of botulinum toxins Mar. 19, 2013
  • Patent Title: Compositions and methods for topical diagnostic and therapeutic transport Jan. 10, 2012
  • Patent Title: Compositions and methods for topical application and transdermal delivery of an oligopeptide Sep. 20, 2011
  • Patent Title: Multi-component biological transport systems Oct. 05, 2010
Government Contracts

Federal grants, loans, and purchases

Government Contracts

Estimated quarterly amount awarded from public contracts

WallStreetBets

Number of mentions of RVNC in WallStreetBets Daily Discussion

RVNC News

Recent insights relating to RVNC

CNBC Recommendations

Recent picks made for RVNC stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in RVNC

RVNC Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view RVNC Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
Back To Top